Moderate osteoporosis itself is beneficial for bones

Area of Science:

• Bone biology and regenerative medicine
• Pharmacology and drug safety
• Gerontology and age-related diseases

Background:

• Increasing reports link anti-osteoporosis drugs to osteonecrosis, notably medication-related osteonecrosis of the jaws (MRONJ).
• This necessitates re-evaluating the dosage and effects of these medications.
• Age-related changes impact mesenchymal stem cells (MSCs), reducing self-renewal and increasing senescence.

Purpose of the Study:

• To hypothesize that primary moderate osteoporosis is beneficial for bone health.
• To propose that excessive treatment should be avoided, focusing instead on vitamin D, calcium, and exercise.
• To explore the role of organic bone tissues in self-repair and immunity.

Main Methods:

• Literature review and synthesis of current evidence on osteoporosis treatments and bone biology.
• Analysis of the impact of anti-osteoporosis drugs on bone's organic components and immune functions.
• Examination of age-related changes in mesenchymal stem cells and their implications for bone repair.

Main Results:

• Anti-osteoporosis drugs may hinder bone's natural self-repair and anti-infection capabilities by increasing mineralization and reducing organic tissue space.
• Excessive treatment can negatively affect long bones and cartilage.
• Moderate osteoporosis may be a natural protective mechanism, enhancing bone immunity and repair capacity.

Conclusions:

• Moderate osteoporosis could be a natural, beneficial state for bone health, supporting immunity and repair.
• Over-treatment with anti-osteoporosis drugs may compromise these vital bone functions.
• Strategies should prioritize enhancing bone's intrinsic repair mechanisms over aggressive pharmaceutical intervention.